VOR BIOPHARMA INC (VOR) Stock News

USA - NASDAQ:VOR - US9290331084 - Common Stock

27.77 USD

-1.66 (-5.64%)

Last: 10/21/2025, 4:46:55 PM

28.04 USD

+0.27 (+0.97%)

After Hours: 10/21/2025, 4:46:55 PM

Technical Analysis

Fundamental Analysis

Analyst Ratings

Earnings Estimates

VOR Latest News, Press Relases and Analysis

All

Press Releases

4 days ago - By: Vor Biopharma

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

4 days ago - By: Vor Biopharma

Vor Bio Announces Late-Breaking Oral Presentation of China Phase 3 IgA Nephropathy Clinical Study at American Society of Nephrology’s Kidney Week 2025

5 days ago - By: Benzinga - Mentions: NVS TVTX

Novartis Strengthens Kidney Disease Pipeline With Promising Data

5 days ago - By: Vor Biopharma

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

2 months ago - By: Stocktwits - Mentions: VTI CNCR

News Image

Vor Bio Stock Jumped 19% Today And Retail Investors Are Eyeing A Breakout Rally: Here’s What’s Happening

5 days ago - By: Vor Biopharma

Vor Bio Announces Publication of China Phase 3 Study of Telitacicept in Systemic Lupus Erythematosus in The New England Journal of Medicine

7 days ago - By: Benzinga - Mentions: NVS

Vor Bio's Collaborator Delivers Positive Results For Telitacicept In Autoimmune Disorder That Impacts Tears

7 days ago - By: Vor Biopharma

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025

7 days ago - By: Vor Biopharma

Telitacicept Demonstrates Clinically Meaningful and Statistically Significant Impact on ESSDAI Compared to Placebo in Late-Breaking China Phase 3 Results in Primary Sjögren’s Disease at ACR 2025

18 days ago - By: Vor Biopharma

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

18 days ago - By: Vor Biopharma

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

22 days ago - By: Vor Biopharma

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025

22 days ago - By: Vor Biopharma

Vor Bio Announces Late-Breaking Poster Presentation of Phase 3 Primary Sjögren’s Disease Clinical Study at ACR Convergence 2025

a month ago - By: Vor Biopharma

Vor Bio Appoints Navid Z. Khan, Ph.D., as Chief Medical Affairs Officer

a month ago - By: RemeGen Co., Ltd

Results of China Phase III Clinical Study of Telitacicept for Generalized Myasthenia Gravis Selected for Oral Presentation at 2025 AANEM Annual Meeting

a month ago - By: Vor Biopharma

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

a month ago - By: Vor Biopharma

Vor Bio Announces Oral Presentation of 48-Week China Phase 3 Generalized Myasthenia Gravis Clinical Study at AANEM

a month ago - By: Vor Biopharma

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

a month ago - By: Vor Biopharma

Vor Bio to Participate in the Stifel 2025 Virtual Immunology and Inflammation Forum

2 months ago - By: Vor Biopharma

Vor Bio Appoints Adi Osovsky, S.J.D. as General Counsel

2 months ago - By: Vor Biopharma

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for IgA Nephropathy

2 months ago - By: Vor Biopharma

Vor Bio to Participate in Upcoming Investor Conferences

2 months ago - By: Vor Biopharma

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Vor Biopharma

Vor Bio Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

2 months ago - By: Vor Biopharma

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

2 months ago - By: Vor Biopharma

Telitacicept Achieved Primary Endpoint in Phase 3 Clinical Study for Primary Sjögren's Disease with Telitacicept, a Dual BAFF/APRIL Inhibitor

3 months ago - By: Vor Biopharma

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

3 months ago - By: Vor Biopharma

Vor Bio Appoints Seasoned Biotech Executive Dallan Murray as Chief Commercial Officer

3 months ago - By: Yahoo Finance - Mentions: SLDB SRPT

Vor Biopharma (VOR) Jumps 10% on Addition of 2 CEOs to Board

3 months ago - By: Vor Biopharma

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

3 months ago - By: Vor Biopharma

Vor Bio Appoints Biotech Industry Leaders Alexander (Bo) Cumbo and Michel Detheux, Ph.D. to Board of Directors

3 months ago - By: Yahoo Finance - Mentions: WFC

H.C. Wainwright Upgrades Vor Biopharma (VOR) to a Buy, Sets a $3 Price Target

3 months ago - By: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Vor Biopharma

Vor Bio Reports Inducement Grant Under Nasdaq Listing Rule 5635(c)(4)

3 months ago - By: Vor Biopharma

Vor Bio Appoints Qing Zuraw, M.D. as Chief Development Officer